GlassScriptPhysician profile
Sachin Mehta
NPI 1619181260
$23,359.76
in general payments reported to CMS, 2019-2025
27 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,296 · 2020: $1,737 · 2021: $4,686 · 2022: $2,662 · 2023: $5,671 · 2024: $3,912 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,063 · Consulting Fee: $2,956 · Travel and Lodging: $916 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,063.43 |
| Consulting Fee | $2,956.25 |
| Travel and Lodging | $915.64 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $4,894.41 | 2020-2024 | Iluvien, Yutiq |
| Novartis Pharmaceuticals Corporation | $4,403.05 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $2,586.64 | 2023-2024 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $2,572.56 | 2022-2025 | Xipere, Stellaris, Visudyne |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,521.09 | 2019 | |
| Cardinal Health 108 LLC | $1,575.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $1,145.57 | 2021-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $812.21 | 2019-2025 | Vabysmo, Susvimo |
| Notal Vision, INC. | $585.33 | 2022 | |
| Astellas Pharma US INC | $542.57 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $369.22 | 2022-2025 | Syfovre |
| Alcon Vision LLC | $344.84 | 2019-2025 | Clareon Panoptix Pro, Unity, Constellation |
| Dutch Ophthalmic, USA | $233.48 | 2019 | |
| Eyevance Pharmaceuticals LLC | $170.73 | 2019 | |
| Glaukos Corporation | $131.75 | 2025 | Idosetr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $108.68 | 2019 | |
| Ani Pharmaceuticals, INC. | $78.09 | 2025 | Yutiq, Iluvien, Purified Cortrophin Gel |
| Harrow Eye, LLC | $54.40 | 2025 | Iheezo |
| Abbvie INC. | $46.84 | 2022-2025 | |
| Biogen, INC. | $44.78 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Genentech, INC. | $34.43 | 2022 | |
| Spark Therapeutics, INC. | $18.61 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $15.66 | 2024 | Callisto Eye |
| Takeda Pharmaceuticals U.S.A., INC. | $13.63 | 2020 | |
| Allergan, INC. | $12.94 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sachin Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.